Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for JW Life Science (제이더블유생명과학(주)) covering the period from January 1, 2021, to September 30, 2021. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for JW Life Science. It provides key financial highlights such as revenue, operating profit, and net income for the 3rd quarter of 2021, comparing them to previous periods. It is a short, structured announcement of financial results rather than a full quarterly report or a report publication announcement. Therefore, it fits the definition of an Earnings Release (ER). 9M 2021
2021-11-10 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증결정) by JW Life Science. It details a financial guarantee provided to an affiliate, including the amount, duration, and board approval details. As this is a specific corporate disclosure regarding financial obligations and capital structure changes that does not fit into the other specific categories like M&A or Share Issues, it is classified as a general Regulatory Filing (RNS).
2021-10-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of JW Holdings and its special related parties in JW Life Science. This type of filing is specifically used to notify the market of significant changes in share ownership (crossing thresholds or changes in control/contracts). In the provided taxonomy, 'Major Shareholding Notification' (MRQ) is the correct category for filings that report changes in significant share ownership levels.
2021-09-29 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of a 10-K. It details specific corrections made to sections such as 'Company Overview', 'Dividend Policy', 'Research and Development', and 'Investment in Other Corporations'. Since it contains substantive financial and operational data and is a formal amendment to the annual report, it is classified as a 10-K. FY 2020
2021-09-01 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for JW Life Science, covering the period from January 1, 2021, to June 30, 2021. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.